Current Rheumatology Reports

, Volume 2, Issue 3, pp 216–224 | Cite as

The role of cytokines, chemokines, and adhesion molecules in the pathogenesis of idiopathic inflammatory myopathies

  • Ingrid E. Lundberg


Cytokines, chemokines, and adhesion molecules are important mediators in chronic inflammation and in immune regulation. In idiopathic inflammatory myopathies (IIM), increased expression of proinflammatory cytokines particularly interleukin (IL)-1a and IL-1b, tumor necrosis factor (TNF)-a and macrophage inflammatory proteins (MIP)-1a, as well as of the inhibitory cytokines transforming growth factor (TGF)-b was observed in muscle. There was no difference in cytokine and chemokine pattern between polymyositis, dermatomyositis, and inclusion body myositis, which could indicate that similar pathogenetic mechanisms are involved in these subsets of myositis. A prominent finding of IL-1a expression in endothelial cells, both in patients with active inflammtion and in patients with chronic persisting muscle weakness without inflammation, makes this an interesting molecule in understanding the mechanisms for the pathogenesis of muscle weakness. Involvement of the blood vessels in the pathogenesis of myositis was further supported by increased expression of adhesion molecules and by a phenotypical expression of endothelial cells, resembling high endothelium venules in all three subsets of IIM. The molecular studies to date indicate a role of the microvessels in the pathogenesis of IIM not only in DM, as was previously suggested, but also in PM and IBM. The studies also indicate that IL-1a could be a target molecule for new therapeutical interventions.


Muscle Tissue Myositis Dermatomyositis Inclusion Body Myositis Inflammatory Myopathy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Dalakas MC: Polymyositis, dermatomyositis, and inclusionbody myositis. N Engl J Med 1991, 325:1487–1498.PubMedCrossRefGoogle Scholar
  2. 2.
    Arahata K, Engel AG: Monoclonal antibody analysis of mononuclear cells in myopathies: I. quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol 1984, 16:193–208.PubMedCrossRefGoogle Scholar
  3. 3.
    Engel AG, Arahata K: Mononuclear cells in myopathies: quantitation of functionally distinct subsets, recognition of antigen-specific cell-mediated cytotoxicity in some diseases, and implications for the pathogenesis of the different inflammatory myopathies. Hum Pathol 1986, 17:704–721.PubMedCrossRefGoogle Scholar
  4. 4.
    Karpati G, Poulior Y, Carpenter S: Expression of immunoreactive major histocompatibility complex products in human skeletal muscles. Ann Neurol 1988, 23:64–72.PubMedCrossRefGoogle Scholar
  5. 5.
    Emslie-Smith AM, Arahata K, Engel AG: Major histocompatibility complex class I antigen expression, immunolocalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies. Hum Pathol 1989, 20:224–231.PubMedCrossRefGoogle Scholar
  6. 6.
    Emslie-Smith AM, Engel AG: Microvascular changes in early and advanced dermatomyositis: a quantitative study. Ann Neurol 1990, 27:343–356.PubMedCrossRefGoogle Scholar
  7. 7.
    DeVere R, Bradley WG: Polymyositis: its presentation, morbidity, and mortality. Brain 1975, 98:637–666.PubMedCrossRefGoogle Scholar
  8. 8.
    Engel AG, Hohfeld R, Banker BQ: The polymyositis and dermatomyositis syndromes. In Myology, edn 2. Edited by Engel AG, Franzini-Armstrong C. New York: McGraw Hill, 1994:1325–1383.Google Scholar
  9. 9.
    Holmdahl R, Malmström V, Vuorio E: Autoimmune recognition of cartilage collagens. Ann Med 1993, 25:251–264.PubMedGoogle Scholar
  10. 10.
    Constantinescu CS, Hilliard B, Fujioka T, et al.: Pathogenesis of neuroimmunologic diseases: experimental models. Immunol Res 1998, 17:217–227.PubMedGoogle Scholar
  11. 11.
    Plotz PH, Dalakas M, Leff RL: Current concepts in the idiopathic inflammatory myopathies:polymyositis, dermatomyositis, and related disorders. Am J Med 1989, 111:143–157.Google Scholar
  12. 12.
    Janeway C, Travers P: T-cell mediated immunity. In Immunobiology-The Immune System in Health and Disease, edn 2. Edited by Janeway C, Travers P. New York: Churchill Livingstone; 1994:1335–1383.Google Scholar
  13. 13.
    Lundberg I, Nyberg P: New developments in the role of cytokines and chemokines in inflammatory myopathies. Curr Opin Rheumatol 1998, 10:521–529.PubMedCrossRefGoogle Scholar
  14. 14.
    Bunch TW, Worthington JW, Combs JJ, et al.: Azathioprine with prednisone for polymyositis: a controlled trial. Ann Intern Med 1980, 92:365—369.PubMedGoogle Scholar
  15. 15.
    Lane RJM, Emslie-Smith A, Mosquera IE, et al.: Clinical, biochemical and histological responses to treatment in polymyositis: a prospective study. J Royal Soc Med 1989, 82:333–338.Google Scholar
  16. 16.
    Lundberg I, Brengman JM, Engel AG: Analysis of cytokine expression in muscle in inflammatory myopathies, Duchenne dystrophy, and non-weak controls. J Neuroimmunol 1995, 63:9–16.PubMedCrossRefGoogle Scholar
  17. 17.
    Lundberg I, Ulfgren AK, Nyberg P, et al.: Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis Rheum 1997, 40:865–874.PubMedCrossRefGoogle Scholar
  18. 18.
    Adams EM, Kirkely J, Eidelman G, et al.: The predominance of b (CC) chemokine transcripts in idiopathic inflammatory muscle diseases. Proc Assoc Am Physicians 1997, 109:275–285.PubMedGoogle Scholar
  19. 19.
    Tews DS, Goebel HH: Cytokine expression profile in idiopathic inflammatory myopathies. J Neuropathol Exp Neurol 1996, 55:342–347.PubMedGoogle Scholar
  20. 20.
    Schubert W, Kontozis L, Sticker G, et al.: Immunofluorescent evidence for presence of interleukin-1 in normal and diseased human skeletal muscle. Muscle Nerve 1988, 11:890–892.PubMedCrossRefGoogle Scholar
  21. 21.
    Authier FJ, Mhiri C, Chazaud B, et al.: Interleukin-1 expression in inflammatory myopathies evidence of marked immunoreactivity in sarcoid granulomas and muscle fibres showing ischaemic and regenerative changes. Neuropathol Appl Neurobiol 1997, 23:132–140.PubMedCrossRefGoogle Scholar
  22. 22.
    Lepidi H, Frances V, Figarella-Branger D, et al.: Local expression of cytokines in idiopathic inflammatory myopahties. Neuropathol Appl Neurobiol 1998, 24:73–79.PubMedCrossRefGoogle Scholar
  23. 23.
    Lindberg C, Oldfors A, Tarkowski A: Local T-cell proliferation and differentiation in inflammatory myopathies. Scand J Immunol 1995, 41:421–426.PubMedCrossRefGoogle Scholar
  24. 24.
    De Bleecker JL, Meire VI, Declerq W, et al.: Immunolocalization of tumor necrosis factor-alpha and its receptors in inflammatory myopahties. Neuromusc Disord 1999, 9:239—246. Increased expression of tumor necrosis factor (TNF)-alpha was detected in macrophages and in dermatomyositis patients also in endothelial cells. The TNF-receptor TNF-R55 was expressed on myonuclei and on regenerating fibers and TNF-R75 in endothelial cells. These results support a role of TNF-a in the pathogenesis of poly-and dermatomyositis.Google Scholar
  25. 25.
    Tateyama M, Nagano I, Yoshioka M, et al.: Expression of tumor necrosis factor-a in muscles of polymyositis. J Neurolog Sci 1997, 146:45–51. TNF-a expression was detected in macrophages in muscle tissue by immunohistochemistry in 3/9 polymyositis patients. This study is a further support for a role of proinflammatory cytokines in polymyositis.CrossRefGoogle Scholar
  26. 26.
    Confalonieri P, Bernasconi P, Cornelio F: Transforming growth factor-b1 in polymyositis and dermatomyositis correlates with fibrosis but not with mononuclear cell infiltrate. Neuropathol Exp Neurol 1997, 56:479–484.Google Scholar
  27. 27.
    Luster AD: Chemokines: chemotactic cytokines that mediate inflammation. N Engl J Med 1998, 338:436–445.PubMedCrossRefGoogle Scholar
  28. 28.
    De Bleecker JL, Engel AG: Expression of cell adhesion molecules in inflammatory myopathies and Duchenne dystrophy. J Neuropathol Exp Neurol 1994, 53:369–376.Google Scholar
  29. 29.
    Bartoccioni E, Gallucci S, Scuderi F et al.: MHC class I, MHC class II and intercellular adhesion molecule-1 (ICAM-1) expression in inflammatory myopathies. Clin Exp Immunol 1994, 95:166–172.PubMedCrossRefGoogle Scholar
  30. 30.
    Tews DS, Goebel HH: Expression of cell adhesion molecules in inflammatory myopathies. J Neuroimmunol 1995, 59:185–194.PubMedCrossRefGoogle Scholar
  31. 31.
    Cid MC, Grau JM, Casademont J, et al.: Leucocyte (endothelial cell adhesion receptors in muscle biopsies from patients with idiopathic inflammatory myopathies (IIM). Clin Exp Immunol 1996, 104:467–473.PubMedGoogle Scholar
  32. 32.
    Iannone F, Cauli A, Yanni G, et al.: T-lymphocyte immunophenotyping in polymyositis and dermatomyositis. Br J Rheumatol 1996, 35:839–845.PubMedCrossRefGoogle Scholar
  33. 33.
    Lundberg I, Kratz AK, Alexandersson H, et al.: Decreased expression of interleukin-1a -b and cell adhesion molecules in muscle tissue following corticosteroid treatment in polymyositis and dermatomyositis. Arthritis Rheum 2000, 43(2):336–348. By immunohistochemical anlysis of repeated muscle biopsies the effect of corticosteroids in vivo was determined. Despite disappearance of inflammatory infiltrates after 4 months of treatment increased expression of MHC class I molecules on muscle fibers and IL-1a and ICAM-1 and VCAM-1 on endothelial cells was still evident in patients with a persisting decreased muscle function.PubMedCrossRefGoogle Scholar
  34. 34.
    Springer TA: Adhesion receptors of the immune system. Nature 1990, 346:425–433.PubMedCrossRefGoogle Scholar
  35. 35.
    Picker LJ, Butcher EC: Physiological and molecular mechanisms of lymphocyte homing. Ann Rev Immunol 1992, 10:561–591.CrossRefGoogle Scholar
  36. 36.
    Bevilacqua MP, Nelson RM, Mannori G, et al.: Endothelialleukocyte adhesion molecules in human disease. Ann Rev Med 1994, 45:361–378.PubMedCrossRefGoogle Scholar
  37. 37.
    Mojcik C, Shevach EM: Adhesion molecules. Arthritis Rheum 1997, 40:991–1004.PubMedCrossRefGoogle Scholar
  38. 38.
    Streeter PR, Rouse BTN, Butcher EC: Immunohistological and functional characterization of a vascular addressin involved in lymphocyte homing into peripheral lymph nodes. J Cell Biol 1988, 107:1853–1862.PubMedCrossRefGoogle Scholar
  39. 39.
    Carota A, Pizzolato GP, Redard M, et al.: Adhesion molecules in HIV-related and idiopathic polymyositis:immunohistochemical studies. Clin Neuropathol 1997, 16:312–318.PubMedGoogle Scholar
  40. 40.
    Jimi T, Wakayama Y, Murahashi M et al.: Expression of selectin families and their ligand sialyl Lewis X in the muscles of inflammatory myopahties: an immunohistochemical study. Intern Med 1999, 38:632–635. The adhesion molecules E-selectin, P-selectin and their ligand Sialyl Lewis X were observed in muscle tissue by immunohistochemistry in patients with poly- and dermatomyositis. E-selectin and P-selectin were expressed on endothelial cells especially on venules and Sialyl Lewis X on blood vessels, leukocytes and on some atrophic fibers. These findings indicate that this could be a pathway for lymphocyte homing to muscle tissue in these disorders.PubMedGoogle Scholar
  41. 41.
    De Bleecker JL, Engel AG, Butcher EC: Peripheral lymphoid tissue-like adhesion molecule expression in nodular infiltrates in inflammatory myopathies Neuromusc Disord 1996, 6:255–260.CrossRefGoogle Scholar
  42. 42.
    Kumamoto T, Abe T, Ueyama H, et al.: Elevated soluble intercellular adhesion molecules-1 in inflammatory myopathy. Acta Neurol Scand 1997, 95:34–37.PubMedGoogle Scholar
  43. 43.
    Nagaraju K, Raben N, Villalba ML, et al.: Costimulatory markers in muscle of patients with idiopathic inflammatory myopathies and in cultured muscle cells. Clin Immunol 1999, 92:161–169. By immunohistochemical staining DM and PM biopsies presence of the costimulatory molecules CTLA4, CD28, CD86 and CD40 on inflammatory cells was observed. CDLA4 and CD28 were also observed on muscle fibers, this observation was confirmed by stimulation of cultured myoblasts with proinflammatory cytokines. The data indicate a novel pathway of interaction between muscle fibers and infiltrating inflammatory cells.PubMedCrossRefGoogle Scholar
  44. 44.
    Henriksson KG, Sandstedt P: Polymyositis: treatment and prognosis. Acta Neurol Scand 1982, 65:280–300.PubMedGoogle Scholar
  45. 45.
    Nyberg P, Wikman AL, Nennesmo I, et al.: Increased expression of interleukin-1a and MHC class I in muscle tissue of patients with chronic, inactive polymyositis and dermatomyositis. J Rheumatol 2000, in press. Patients with chronic inactive myositis with persistent muscle weakness were investigated by muscle biopsies and MRI. Increased expression of IL-1a was detected on endothelial cells compared to normal controls as well as increased MHC class I expression on muscle fibers indicating that these molecules could play a role in the pathogenesis of the muscle weakness in myositis patients.Google Scholar
  46. 46.
    Matsubara S, Hirai S, Sawa Y: Pulsed intravenous methylprednisolone therapy for inflammatory myopathies: evaluation of the effect by comparing two consecutive biopsies from the same muscle. J Neuroimmunol 1997, 76:75–80.PubMedCrossRefGoogle Scholar
  47. 47.
    Dalakas MC: Clinical benefits and immunopathological correlates of intravenous immune globulin in the treatment of inflammatory myopathies. Clin Exp Immunol 1996, 104:55–60.PubMedGoogle Scholar
  48. 48.
    Leff RL, Miller FW, Hicks J, et al.: The treatment of inclusion body myositis:A retrospective review and a randomized, prospective trial of immunosuppressive therapy. Medicine 1993, 72:225–235.PubMedCrossRefGoogle Scholar
  49. 49.
    Pruitt NJ, Showalter CM, Engel AG: Sporadic inclusion body myositis: counts of different types of abnormal fibers. Ann Neurol 1996, 39:139–143.PubMedCrossRefGoogle Scholar
  50. 50.
    Bahron RJ, Amato AA, Sahenk Z, et al.: Inclusion body myositis: explanation for poor response to immunosuppressive therapy. Neurol 1995, 45:1302–1304.Google Scholar
  51. 51.
    Mantovani A, Bussolino F, Dejana E: Cytokine regulation of endothelial cell function. FASAB J 1992, 6:2591–2599.Google Scholar
  52. 52.
    Speiser P, Zeillinger R, Wiltschke C et al.: IL-1 alpha mediated HLA class II (DR) antigen up-regulation in a human ductal breast carcinoma cell line ZR-75-1. Neoplasma 1993, 40:137–140.PubMedGoogle Scholar
  53. 53.
    Wicks IP, Leizer T, Wawryk SO, et al.: The effect of cytokines on the expression of MHC antigens and ICAM-1 by normal and transformed synoviocytes. Autoimmunity 1992, 12:13–19.PubMedGoogle Scholar
  54. 54.
    Nagaraju K, Raben N, Merritt G et al.: A variety of cytokines and immunologically relevant surface molecules are expressed by normal human skeletal muscle cells under proinflammatory stimuli. Clin Exp Immunol 1998, 113:407–414. In cultured muscle cells increased expression of MHC class I and class II molecules, intercellular adhesion molecule-1 as well as IL-6 and transforming growth factor-beta was induced by stimulation with proinflammatory cytokines such as IL-1a and IL-1b. These results show that muscle cells have an inherent ability to express and respond to a variety of cytokines and chemokines.PubMedCrossRefGoogle Scholar
  55. 55.
    Kalovidouris AE: The role of cytokines in polymyositis: interferon-gamma induces class II and enhances class I major histocompatibility complex antigen expression on cultured human muscle cells. J Lab Clin Med 1992, 120:244–251.PubMedGoogle Scholar
  56. 56.
    Sikorski EE, Hallmann R, Berg EL, et al.: The Peyer’s patch high endothelial receptor for lymphocytes, the mucosal vascular addressin, is induced on a murine endothelial cell line by tumor necrosis factor-alpha and IL-1. J Immunol 1993, 151:5239–5250.PubMedGoogle Scholar
  57. 57.
    Park JH, Vital TL, Ryder NM, et al.: Magnetic resonance imaging and P-31 magnetic resonance spectroscopy provide unique quantitative data useful in the longitudinal management of patients with dermatomyositis. Arthritis Rheum 1994, 37:736–746.PubMedCrossRefGoogle Scholar
  58. 58.
    Shreeniwas R, Koga S, Karakurum M, et al.: Hypoxia-mediated induction of endothelial cell interleukin-1 alpha:an autocrine mechanism promoting expression of leukocyte adhesion molecules on the vessel surface. J Clin Invest 1992, 90:2333–2339.PubMedCrossRefGoogle Scholar
  59. 59.
    Falanga V, Qian SW, Danielpour D, et al.: Hypoxia upregulates the synthesis of TGF-beta 1 by human dermal fibroblasts. J Invest Dermatol 1991, 97:634–637.PubMedCrossRefGoogle Scholar
  60. 60.
    Niinikoski J, Paljarvi L, Laato M, et al.: Muscle hypoxia in myositis. J Neurol Neurosurg Psychiat 1986, 49:1455.PubMedCrossRefGoogle Scholar
  61. 61.
    Ogawa S, Shreeniwas R, Brett J, et al.: The effect of hypoxia on capillary endothelial cell function: modulation of barrier and coagulant function. Br J Haematol 1990, 75:517–524.PubMedGoogle Scholar
  62. 62.
    Fang CH, Li BG, James H, et al.: Cytokines block the effects of insulin-like growth factor-I (IGF-I) on glucose uptake and lactate production in skeletal muscle but do not influence IGF-I-induces changes in protein turnover. Shock 1997, 8:362–367.PubMedCrossRefGoogle Scholar
  63. 63.
    Leon-Monzon M. Interleukin-1 is toxic to human muscle. Neurology 1994, 44(S2):A132.Google Scholar

Copyright information

© Current Science Inc 2000

Authors and Affiliations

  • Ingrid E. Lundberg
    • 1
  1. 1.Department of RheumatologyKarolinska HospitalStockholmSweden

Personalised recommendations